<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04141592</url>
  </required_header>
  <id_info>
    <org_study_id>247449</org_study_id>
    <nct_id>NCT04141592</nct_id>
  </id_info>
  <brief_title>Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease: Cross-sectional Comparative Study Between Patients and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Homerton University Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify key characteristics of the tissue resident and peripherally circulating
      immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota
      in non-alcoholic fatty liver disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will collect tissue, blood, stool, urine and saliva samples
      at the same time in order to enable a comprehensive disease phenotyping and ability to
      compare immunological, microbiological and metabolic features in patients with varying stages
      of NAFLD and healthy controls. To date there are limited published data evaluating
      simultaneously-obtained samples from adipose, gut and liver tissue and peripheral blood in
      NAFLD. The majority of participants in this study will be recruited from the bariatric
      surgery services enabling multiple tissue samples to be collected at time of surgery with
      minimal additional risk to participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">September 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of weight loss surgery upon Non-alcoholic steatohepatitis</measure>
    <time_frame>Two years</time_frame>
    <description>Proportion of patients developing resolution of NASH after weight loss surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of weight loss surgery upon Non-invasive measures of fibrosis</measure>
    <time_frame>Six months</time_frame>
    <description>Evaluation of changes in liver transient elastography post weight loss surgery</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease Without Non-Alcoholic Steatohepatitis (Disorder)</condition>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>non-obese individuals without fatty liver disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-alcoholic fatty liver disease without NASH</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-alcoholic steatohepatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese without non-alcoholic fatty liver disease</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric Surgery</intervention_name>
    <description>Already clinically indicated surgical procedures</description>
    <arm_group_label>Non-alcoholic fatty liver disease without NASH</arm_group_label>
    <arm_group_label>Non-alcoholic steatohepatitis</arm_group_label>
    <arm_group_label>Obese without non-alcoholic fatty liver disease</arm_group_label>
    <other_name>Upper GI surgery</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMCs, serum, plasma, liver tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be identified from outpatient clinics of Bariatric, Gastroenterology, and
        Hepatology services at Homerton and King College Hospitals in addition to Gastroenterology
        outpatients from the Barts Health NHS Trust. Healthy control participants will be
        identified from patients undergoing outpatient assessment, gastroscopy or surgery for other
        non-malignant gastrointestinal disorders at hospital sites.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Confirmed non-alcoholic Fatty liver disease (diagnosed clinically, radiologically or
             histologically)

          -  If diabetic, Diagnosed with Type 2 Diabetes Mellitus

        OR

        • Healthy Control: no diagnosis of any liver condition including NAFLD

        o NAFLD excluded by Fibroscan Controlled Attenuation Parameter (CAP) score of &lt;222 dB/m

        Exclusion Criteria:

          -  Unwilling or unable to give informed consent

          -  Type 1 Diabetes Mellitus

          -  Other form of liver disease (other than NAFLD)

             o Viral hepatitis, Auto-immune hepatitis, primary sclerosing cholangitis, primary
             biliary cholangitis, haemochromatosis, Sarcoidosis, cystic fibrosis, sickle cell
             disease

          -  Taking medication associated with liver dysfunction (except methotrexate)

          -  Auto-immune disease which in the investigator's opinion may confound immune profiling

          -  Concomitant immunosuppressive medications (except methotrexate, short course oral
             steroids or inhaled corticosteroids)

          -  Currently pregnant

          -  Any major organ transplant (excluding corneal or hair transplant)

          -  Regular alcohol intake greater than 14 units a week for female participants and 21
             units a week for male participants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Alazawi, MBBS MA Phd</last_name>
    <phone>+442078822308</phone>
    <email>w.alazawi@qmul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Brindley, MBBS BSc MRCP</last_name>
    <phone>+442078827198</phone>
    <email>james.brindley@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Homerton University Hospital Foundation Trust</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E9 6SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemary Mullett</last_name>
      <phone>+44208 510 5117</phone>
      <email>rosemary.mullett@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2019</study_first_posted>
  <last_update_submitted>October 24, 2019</last_update_submitted>
  <last_update_submitted_qc>October 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

